Abstract:BACKGROUND: For the recent prevention of chemotherapy-induced nausea and vomiting (CINV) in children aged 6 months and older, neurokinin-1(NK-1) receptor antagonists were suggested. However, there is little information available on how to select NK-1 receptor antagonists for pediatric patients, such as aprepitant and fosaprepitant. METHODS: Children between the ages of 2 and 12 who were scheduled to undergo chemotherapy that was either mildly or strongly emetic were randomly randomized to receive fosaprepitant (arm-A) or aprepitant (arm-B). For the children in arm-A, ondansetron and dexamethasone were administered intravenously, followed by a fosaprepitant infusion. The identical medications were administered to children selected for arm-B, with the exception that aprepitant was used instead of fosaprepitant. Dexamethasone and ondansetron were continuously administered for 48 hours following the conclusion of treatment. The proportion of patients who experienced a complete response (CR), which is defined as no vomiting, no retching, and no need for rescue medication, during the acute phase (0-24 hours after the last dose of chemotherapy) was administered, was the study's main end point. The percentage of patients who achieved a CR overall and within the delayed period (24-120 hours) following the last chemotherapy treatment were considered secondary end goals. RESULTS : A total of 108 patients were examined (55 in the fosaprepitant arm and 53 in the aprepitant arm). In the acute phase (95% vs 79%, P =0.018, P<0.05), delayed phase (71% vs 66%, P =0.586), and overall phase (69% vs 57%, P =0.179), CR rates were greater in the fosaprepitant arm than in the aprepitant arm. Additionally, there is no difference between the aprepitant arm (11%) and the fosaprepitant arm (7%) in terms of the desire for rescue anti-emetics. CONCLUSIONS: Adding fosaprepitant to ondansetron and dexamethasone is more beneficial than adding aprepitant for preventing CINV in the acute phase. Fosaprepitant and aprepitant, however, do not significantly differ from one another for prevention throughout the delayed and overall phases. This study was approved by IRB of Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine (No. SCMCIRB-K2020120-2), and it was prospectively registered with the ClinicalTrials.gov on April 22, 2021 (reference number: NCT04873284 ).

Prevention and treatment of anticipatory chemotherapy‐induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update

Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023

[Chemotherapy-induced nausea and vomiting in pediatric oncology patients: 2023 recommendations from the Supportive Care Committee of the French Society of Cancer in Children and Adolescents]

Outcomes of chemotherapy-induced nausea and vomiting guideline adherence in pediatric and adult patients: a systematic review

Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey

2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients

Pediatric oncology provider perspectives and patient/family perceptions of chemotherapy‐induced nausea and vomiting management: Experiences at an academic medical center

Chinese expert consensus on prevention and treatment of delayed nausea and vomiting (2022 Edition)

2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents

Anti-Emetics in Children Receiving Chemotherapy for Solid Tumors and Leukemia: Pharmacology and Optimization of Therapy for Nausea and Vomiting

Risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy

The Use of Complementary and Integrative Medicine in Combination With Pharmacological Antiemetics to Address Chemotherapy-Induced Nausea and Vomiting in Pediatric Oncology: A Scoping Review

Clinical practice guideline-inconsistent chemotherapy-induced vomiting prophylaxis in pediatric cancer patients in community settings: A Children's Oncology Group study

Aprepitant versus a single dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: A randomized, parallel-group, phase III trial

Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single‐center review

Evaluation of chemotherapy-induced nausea and vomiting in pediatric patients with high-grade glioma treated with lomustine—a case series

Chemotherapy-induced nausea and vomiting among cancer patients in Shanghai:a cross-sectional study

Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation

Vomiting despite adherence to guidelines: Suboptimal control of vomiting in pediatric cancer patients

Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success

Efficacy and Safety of Neurokinin-1 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting: Systematic Review and Meta-analysis of Randomized Controlled Trials.